Daria Chernushevich
Research Subjects
Research Interests
Daria Chernushevich has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexander V. Filatov
National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, Moscow, Russia
1 shared publication - Alla Olegovna Litovkina
National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia; Peoples' Friendship University of Russia
1 shared publication - Artem Mikhailov
Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia
1 shared publication - Dmitry Anatolievich Kudlay
Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia
1 shared publication - Evgeniy Smolnikov1 shared publication
- Maria G. Byazrova
National Research Center Institute of Immunology FMBA of Russia Moscow Russian Federation
1 shared publication
Latest Publications
- Open Access
- 25 October 2023
- Published by MDPI AG in Preprints.org
Long-Term Impact of Dupilumab Treatment on Systemic Cytokine Profile in Atopic Dermatitis Patients: A Cross-Sectional Study
Atopic dermatitis (AD), a T2 inflammatory skin condition, is widely recognized as one of the most prevalent chronic and recurrent skin disorders. One of the most effective therapy for treating moderate-to-severe AD is Dupilumab, a monoclonal antibody that blocks both IL-4 and IL-13 signaling. At the same time, no comprehensive analysis of cytokines profile was made in AD patients undergoing Dupilumab therapy. The primary objective of our research was to examine the levels of main cytokines to better understanding systemic immune response in AD and to identify potential biomarkers of the effectiveness of Dupilumab treatment. AD patients demonstrated significant clinical improvements one year after initializing of Dupilumab therapy. We identified 16 cytokines that showed major difference between Dupilumab-treated patients and patients without Dupilumab therapy. Six cytokines showed correlation with AD severity and the efficacy of Dupilumab therapy. Jointly revealed cytokines could potentially predict the effectiveness of Dupilumab treatment and help to choose the precision target therapy in AD patients as well.
- 25 October 2023
- Published by MDPI AG in Preprints.org
Open AccessLong-Term Impact of Dupilumab Treatment on Systemic Cytokine Profile in Atopic Dermatitis Patients: A Cross-Sectional Study
Atopic dermatitis (AD), a T2 inflammatory skin condition, is widely recognized as one of the most prevalent chronic and recurrent skin disorders. One of the most effective therapy for treating moderate-to-severe AD is Dupilumab, a monoclonal antibody that blocks both IL-4 and IL-13 signaling. At the same time, no comprehensive analysis of cytokines profile was made in AD patients undergoing Dupilumab therapy. The primary objective of our research was to examine the levels of main cytokines to better understanding systemic immune response in AD and to identify potential biomarkers of the effectiveness of Dupilumab treatment. AD patients demonstrated significant clinical improvements one year after initializing of Dupilumab therapy. We identified 16 cytokines that showed major difference between Dupilumab-treated patients and patients without Dupilumab therapy. Six cytokines showed correlation with AD severity and the efficacy of Dupilumab therapy. Jointly revealed cytokines could potentially predict the effectiveness of Dupilumab treatment and help to choose the precision target therapy in AD patients as well.